TYK Medicines, Inc (Stock Code: 2410) has reported that its investigational Class 1 new drug, Asandeutertinib (TY-9591), has been listed for priority review by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA). The drug is intended for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations (exon 19 deletion or exon 21 L858R), together with central nervous system metastases.

According to the announcement, Asandeutertinib (TY-9591) features high systemic and intracranial response rates in clinical studies, showing notable benefits for patients with brain metastases from NSCLC. The pivotal Phase II study results indicate that Asandeutertinib (TY-9591) delivers superior efficacy compared to other third-generation EGFR-TKIs, potentially filling an unmet clinical need for safer and more effective therapy options.

While its inclusion in the priority review list signifies faster evaluation, the final approval is subject to comprehensive technical assessment and administrative review by the NMPA. The company also highlights the inherent uncertainties in the drug development process, noting that there is no guarantee of ultimate marketing authorization. TYK Medicines, Inc advises all investors to remain aware of possible outcomes and the associated risks. The firm will continue to advance the product and fulfill disclosure obligations as required by relevant regulations.